Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Thursday

Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to issue its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of ($0.7279) per share and revenue of $166.0290 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same period in the previous year, the company earned ($0.30) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 43.3% on a year-over-year basis. On average, analysts expect Mirum Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $114.20 on Tuesday. The firm has a market cap of $6.96 billion, a PE ratio of -8.39 and a beta of 0.48. Mirum Pharmaceuticals has a 52-week low of $50.25 and a 52-week high of $130.00. The business’s 50 day moving average price is $109.14 and its two-hundred day moving average price is $100.79. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 2,721 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total value of $326,520.00. Following the sale, the senior vice president directly owned 3,114 shares in the company, valued at approximately $373,680. The trade was a 46.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.27, for a total value of $2,445,400.00. Following the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $23,758,161.43. The trade was a 9.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 65,315 shares of company stock worth $6,991,928. Insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC increased its position in Mirum Pharmaceuticals by 21.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the last quarter. State Street Corp grew its stake in shares of Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after buying an additional 797,088 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after buying an additional 672,118 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Mirum Pharmaceuticals by 709.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after buying an additional 536,674 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in shares of Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock valued at $28,560,000 after acquiring an additional 371,999 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on MIRM shares. Citizens Jmp lifted their price target on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a research report on Monday, June 15th. CLSA set a $146.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Raymond James Financial reiterated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. TD Cowen upped their price objective on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $143.40.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.